Neoangiogenesis and coronary atherosclerosis: Diagnostic value of a novel biochemical marker placenta growth factor in patients with ischemic heart disease

Kardiologiya

Volumn 46, Issue 11, 2006, Pages 9-15

  Shevtchenko, A O ^a   Shevtchenko, O P ^a   Orlova, O V ^a   Tulikov, M V ^a  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Inflammation; Ischemic heart disease; Neoangiogenesis; Placenta growth factor; Prognosis

Indexed keywords

BIOLOGICAL MARKER; GROWTH PROMOTOR; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; DIFFERENTIAL DIAGNOSIS; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GROWTH SUBSTANCES; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY PROTEINS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33845956991     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005;112:1813-1824.
2. Jeziorska M., Woolley D.E. Local neovascularization and cellular composition within vulnerable regions of atherosclerotic plaques of human carotid arteries. J Pathol 1999;188:189-196.
3. Virmani R., Kolodgie F.D., Burke A.P. et al. Atherosclerotic Plaque Progression and Vulnerability to Rupture: Angiogenesis as a Source of Intraplaque Hemorrhage. Arterioseler Thromb Vasc Biol 2005;25:2054-2061.
4. Tenaglia A.N., Peters K.G., Sketch M.H. Jr., Annex B.H. Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 1998;135:10-14.
5. Tjwa M., Luttun A., Autiero M., Carmeliet P. VEGF and PIGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tiss Res 2003;314:5-14.
6. Apple F.S., Wu A.H., Mair J. et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005;51:810-824.
7. Cao Y., Ji W.R., Qi P. et al. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Comm 1997;235:493-498.
8. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850.
9. Simons M. Angiogenesis: Where Do We Stand Now? Circulation 2005;111:1556-1566.
10. Pipp F., Heil M., Issbrucker K. et al. VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circulat Res 2003;92:4:378-385.
11. Bjorndahl M., Cao R., Eriksson A., Cao Y. Blockage of VEGF-Induced Angiogenesis by Preventing VEGF Secretion. Circulat Res 2004;94:1443-1450.
12. Koester W. Endareritis and arteritis. Berl Klin Wschr 1876;13:454-455.
13. O'Brien E.R., Garvin M.R., Dev R. et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145:883-894.
14. Moreno P.R., Purushothaman K.R., Fuster V. et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-2038.
15. Moulton K.S., Vakili K., Zurakowski D. et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100:4736-4741.
16. Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-840.
17. Khurana R., Moons L., Shafi S. et al. Placental growth factor (PIGF) promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005;111:2828-2836.
18. Melamed-Frank M., Lache O., Enav B.I. et al. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood 2001;98:3693-3698.
19. Huber C., Batchelor J.R., Fuchs D. et al. Immune response associated production of neopterin: release from macrophages primarily under control of interferon. J Exp Med 1984;160:310.
20. Gupta S., Fredericks S., Schwartzman R.A. et al. Serum neopterin in acute coronary syndromes. Lancet 1997;349:1252.
21. Selvaraj S.K., Giri R.K., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102:1515.
22. Kwon H.M., Sangiorgi G., Ritman E.L. et al. Adventitial vasa vasorum in balloon-injured coronary arteries: visualization and quantitation by a microscopic three-dimensional computed tomography technique. J Am Coll Cardiol 1998;32:2072-2079.
23. Celletti F.L., Waugh J.M., Amabile P.G. et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-429.
24. Moulton K.S., Heller E., Konerding M.A. et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-1732.